21/12/2014 09:24:32 Free Membership Login

Cyprotex News (LSE:CRX)

11/19/20148:41AMALNCDIRECTOR DEALINGS: Cyprotex Non-Executive Director Purchases Shares
LONDON (Alliance News) - Cyprotex PLC Wednesday said Non-Executive Director Ralph Harris purchased 10,000 shares at a price of 39.0 pence per share on Tuesday. Following the transaction, Harris holds 210,514 shares, representing 0.94% of the issued share capital in the company. Cyprotex shares were down 1.3% to 39.00 pence... More...>>
11/14/201411:18AMALNCDIRECTOR DEALINGS: Cyprotex Chief Executive And Wife Buy Shares
LONDON (Alliance News) - Cyprotex PLC said Friday that Chief Executive Anthony Baxter bought 11,000 shares in the company at 40 pence each. His wife Helen Baxter has also bought 5,200 shares at the same price. Following these transactions Baxter has an interest in 132,374 shares, or less than 1.0%. Shares in Cyprotex are... More...>>
11/14/20142:53AMALNCCyprotex Warns On Full Year Amid Development Delays, Weak Demand
LONDON (Alliance News) - Cyprotex PLC on Friday issued a profit warning for the full year as the group came under pressure from delays in its development work and weaker-than-anticipated demand. The contract research organisation said the delays highlighted in its half-year results had continued to exacerbate in the second... More...>>
10/14/20145:11AMALNCCyprotex Launches Improved Version Of SenCeeTox Technology
LONDON (Alliance News) - Cyprotex PLC said Tuesday that it has launched an improved version of its SenCeeTox technology, a model used to predict 'in vitro' skin sensation. Cyprotex acquired the technology with CeeTox Inc in January. It is an in vitro model that uses multiple endpoints to predict skin sensation. In the... More...>>
10/14/20142:00AMRNSNONCyprotex PLC Enhanced SenCeeTox® technology
TIDMCRX RNS Number : 1708U Cyprotex PLC 14 October 2014 14 October 2014 Cyprotex PLC Enhanced SenCeeTox(R) technology for prediction of in vitro skin sensitisation Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces significant advances in its SenCeeTox(R) model for the... More...>>
10/09/20144:30AMALNCCyprotex Now Able To Offer Full Range Of In Vitro Drug Transporter Assays
LONDON (Alliance News) - Cyprotex PLC Thursday said it has expanded its in-house drug transporter services, and can now offer a full range of in vitro drug transporter assays that are recommended by the regulatory authorities. The contract research organisation has recently bought two transport services, and got a permit... More...>>
10/09/20142:01AMRNSNONCyprotex PLC Expansion of Drug Transporter Capabilities
TIDMCRX RNS Number : 8182T Cyprotex PLC 09 October 2014 9 October 2014 Cyprotex PLC Expansion of Drug Transporter Capabilities Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the expansion of its in-house drug transporter services. Cyprotex can now offer the full range... More...>>
10/01/20144:22AMALNCCyprotex Buys New Instruments To Expand Toxicology Facility
LONDON (Alliance News) - Cyprotex PLC said Wednesday that it had expanded its toxicology facility to include high content 3D tissue analysis and advanced mitochondrial toxicity analysis after buying new instruments. Cyprotex bought new instruments including a Thermo Scientific ArrayScan XTI high-content screening platform... More...>>
10/01/20142:00AMRNSNONCyprotex PLC Expansion of Toxicology Capabilities
TIDMCRX RNS Number : 0273T Cyprotex PLC 01 October 2014 1(st) October 2014 Cyprotex PLC ("Cyprotex" or the "Company") Expansion of Toxicology Capabilities Cyprotex PLC (AIM:CRX; www.cyprotex.com), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the expansion of its toxicology capabilities to... More...>>
09/09/20144:54AMALNCCyrpotex: In Vitro Skin Sensitisation Test Using KeratinoSens Launched
LONDON (Alliance News) - Cyprotex PLC Tuesday said a new in vitro screening service for determining skin sensitisation has been launched using the KeratinoSens test method. The new launch of the test comes after the European Union Reference Laboratory for Alternatives to Animal Testing in February recommended KeratinoSens... More...>>
09/09/20142:01AMRNSNONCyprotex PLC Launch of KeratinoSensTM Service
TIDMCRX RNS Number : 1356R Cyprotex PLC 09 September 2014 9(th) September 2014 Cyprotex PLC Launch of KeratinoSens(TM) Service An OECD guideline compliant, in vitro assay for skin sensitisation Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the launch of a new in vitro... More...>>
09/04/20144:46AMALNCCyprotex Joins Comprehensive In Vitro Proarrythmia Assay Initiative
LONDON (Alliance News) - Cyprotex PLC Thursday said it has been selected as a testing facility in the Comprehensive in vitro Proarrythmia Assay initiative which aims to devise new approaches for cardiac safety testing. "Cyprotex is actively involved in the CiPA paradigm and is a leader in the field of in vitro cardiac... More...>>
09/04/20142:00AMRNSNONCyprotex PLC Cyprotex joins CiPA initiative
TIDMCRX RNS Number : 7951Q Cyprotex PLC 04 September 2014 4th September 2014 Cyprotex PLC Cyprotex joins CiPA initiative Selected as testing facility for new in vitro cardiac safety testing strategies Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announces its membership and its selection... More...>>
08/21/20144:58AMALNCCyprotex Seeks Loan Note Listing On Cayman Islands Stock Exchange
LONDON (Alliance News) - Cyprotex PLC Thursday said it has written to holders of its GBP3.0 million fixed rate redeemable loan notes and GBP4.0 million fixed rate convertible loan notes to seek their consent for the notes to be listed on the Cayman Islands Stock Exchange. "The board believes that a listing of the loan... More...>>
10/01/20132:00AMRNSNONCyprotex PLC Expands into Biohub, Alderley Park
TIDMCRX RNS Number : 3331P Cyprotex PLC 01 October 2013 Cyprotex PLC ("Cyprotex" or "the Company") Cyprotex to expand its UK facility into BioHub at Alderley Park 1st October 2013; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation, announced today its plans for the expansion of its UK facility... More...>>
07/18/20132:00AMRNSNONCyprotex PLC Launch of new eCiphrNeuro service
TIDMCRX RNS Number : 5797J Cyprotex PLC 18 July 2013 Cyprotex to launch eCiphrNeuro, a new service to evaluate neuronal activity 18 July, 2013 - Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation, today extends its eCiphr range with the launch of a new service, eCiphrNeuro, using microelectrode... More...>>
07/11/20132:00AMRNSNONCyprotex PLC Launch of New Toxicity Guide
TIDMCRX RNS Number : 0620J Cyprotex PLC 11 July 2013 Cyprotex PLC ("CRX" or "the Company" or "the Group") Cyprotex launches new 'Mechanisms of Drug-Induced Toxicity' guide 11 July, 2013 - Cyprotex PLC, a specialist ADME-Tox Contract Research Organisation, today announces the launch of its third educational guide. Following... More...>>
02/14/20132:00AMRNSNONCyprotex PLC Launch of new cardiotoxicity service-eCiphrCardio
TIDMCRX RNS Number : 8385X Cyprotex PLC 14 February 2013 Cyprotex launches a new cardiotoxicity service - eCiphrCardio 14 February, 2013 - Cyprotex PLC (AIM:CRX), the specialist preclinical contract research organisation (CRO), today announces the launch of eCiphrCardio, an assay to assess potential cardiotoxicity of compounds... More...>>
10/30/201211:28AMDJNCyprotex in Collaborative Research Agreement with Pfizer
LONDON--Cyprotex PLC (CRX.LN), the preclinical ADME-Tox services company, Tuesday announced a collaborative research agreement between its wholly owned subsidiary Apredica LLC and Pfizer Inc. (PFE). MAIN FACTS: -No financial details have been disclosed -The deal extends over an eighteen month period and is split into two... More...>>
08/02/20122:01AMRNSNONCyprotex PLC Updated Regulatory Guidance Booklet
TIDMCRX RNS Number : 1102J Cyprotex PLC 02 August 2012 2(nd) August 2012 Cyprotex PLC Cyprotex launch their updated Drug-Drug Interaction Regulatory Guidance booklet to reflect the new FDA and EMA guidelines Cyprotex PLC (AIM:CRX), the ADME Tox specialists, have today launched an update of their popular Drug-Drug Interaction... More...>>

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us lse crx141221 09:24